UPDATE ON AVAILABILITY OF NOVAVAX/NUVAXOVID COVID-19 VACCINE

From 1 January 2025, the Novavax/Nuvaxovid COVID-19 vaccine will not be available under the National Vaccination Programme (NVP). The existing XBB1.5 formulation of the vaccine is no longer supplied by the manufacturer, and the current stocks of this formulation in Singapore will expire on 31 December 2024.

2.             Eligible individuals who wish to receive the existing formulation of the Novavax/Nuvaxovid vaccine will have to do so by 31 December 2024. Individuals receiving the Novavax/Nuvaxovid vaccine as an additional dose should do so around one year (and at least five months) from the last vaccine dose.

3.             Novavax is in the process of filing for regulatory approval for its updated COVID-19 vaccine formulation. Further updates will be provided when Novavax has successfully filed for regulatory approval and supply is available in Singapore.

4.             The updated JN.1 mRNA vaccines (Pfizer-BioNTech/Comirnaty and Moderna/Spikevax) will continue to be available under the NVP. Members of the public can visit https://gowhere.gov.sg/vaccine for the nearest vaccination sites and the vaccine types offered. Individuals may book an appointment at a Healthier SG General Practitioner clinic via https://vaccine.gov.sg/covid, or at a polyclinic via the HealthHub booking system.

5.             Mobile vaccination teams offering COVID-19 vaccination will continue to be deployed across the island. Members of the public can visit https://go.gov.sg/mvts for the latest schedule

6.             We encourage everyone, especially those aged 60 years and above or medically vulnerable, to remain updated with their vaccination based on the prevailing recommendations.